News Article
Jun 20, 2017
Microbiotica to Present at Microbiome Drug Development Summit

27-29 June 2017, Boston

Cambridge, UK, 20 June 2017 – Microbiotica, a leading player in microbiome-based therapeutics, announces that its Chief Scientific Officer Dr Trevor Lawley will present at this year’s Microbiome Drug Development Summit, 27-29 June in Boston.

Dr Lawley’s talk ‘Culturing the “unculturable” to harness the therapeutic potential of the human intestinal microbiome’ will take place at 9.00am on Wednesday 28 June. The presentation will focus on his pioneering work that allows culturing, genomic and functional characterisation of the majority of the intestinal microbiota.

Microbiotica, which was spun-out of the Wellcome Trust Sanger Institute in 2016, was formed around ground-breaking research led by Dr Lawley and is focused on microbiome biology and its use in medicine, covering both novel bacterial therapeutics and patient diagnostics. Cambridge Innovation Capital and IP Group co-invested £8 million into the start-up.

Dr Mike Romanos, CEO of Microbiotica, said: “Over the past decade there has been a groundswell of research demonstrating how pivotal the human microbiome is to health and disease. Trevor’s research at the Sanger Institute has transformed our ability to culture, sequence and characterise bacteria associated with biological phenotypes, opening up new avenues for therapeutic and biomarker discovery, which Microbiotica is translating and commercialising.”

The Microbiome Drug Development Summit is a meeting dedicated to accelerating the discovery, clinical development and commercialisation of a new generation of microbiome-based therapeutics. This year’s event runs from 27-29 June and will be held at Aloft Boston Seaport, Boston.